These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 31665949)

  • 1. Economic burden associated with inadequate antidepressant medication management among patients with depression and known cardiovascular diseases: insights from a United States-based retrospective claims database analysis.
    Bangalore S; Shah R; Gao X; Pappadopulos E; Deshpande CG; Shelbaya A; Prieto R; Stephens J; Chambers R; Schepman P; McIntyre RS
    J Med Econ; 2020 Mar; 23(3):262-270. PubMed ID: 31665949
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular hazards of insufficient treatment of depression among patients with known cardiovascular disease: a propensity score adjusted analysis.
    Bangalore S; Shah R; Pappadopulos E; Deshpande CG; Shelbaya A; Prieto R; Stephens J; McIntyre RS
    Eur Heart J Qual Care Clin Outcomes; 2018 Oct; 4(4):258-266. PubMed ID: 29893803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients.
    Li G; Zhang L; DiBernardo A; Wang G; Sheehan JJ; Lee K; Reutfors J; Zhang Q
    PLoS One; 2020; 15(9):e0238843. PubMed ID: 32915863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder.
    Ta JT; Sullivan SD; Tung A; Oliveri D; Gillard P; Devine B
    J Manag Care Spec Pharm; 2021 Feb; 27(2):223-239. PubMed ID: 33506730
    [No Abstract]   [Full Text] [Related]  

  • 5. Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis.
    Pilon D; Joshi K; Sheehan JJ; Zichlin ML; Zuckerman P; Lefebvre P; Greenberg PE
    PLoS One; 2019; 14(10):e0223255. PubMed ID: 31600244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions.
    Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
    J Manag Care Spec Pharm; 2020 Aug; 26(8):996-1007. PubMed ID: 32552362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis.
    Gauthier G; Guérin A; Zhdanava M; Jacobson W; Nomikos G; Merikle E; François C; Perez V
    BMC Psychiatry; 2017 Jun; 17(1):222. PubMed ID: 28629442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
    Seetasith A; Greene M; Hartry A; Burudpakdee C
    J Med Econ; 2018 Sep; 21(9):888-901. PubMed ID: 29862860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Humanistic and Economic Burden Associated with Major Depressive Disorder: A Retrospective Cross-Sectional Analysis.
    Culpepper L; Martin A; Nabulsi N; Parikh M
    Adv Ther; 2024 May; 41(5):1860-1884. PubMed ID: 38466558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic burden and antidepressant treatment patterns among patients with major depressive disorder in the United States.
    Zhu L; Ferries E; Suthoff E; Namjoshi M; Bera R
    J Manag Care Spec Pharm; 2022 Nov; 28(11-a Suppl):S2-S13. PubMed ID: 36242598
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment patterns, health care resource utilization, and costs associated with use of atypical antipsychotics as first vs subsequent adjunctive treatment in major depressive disorder.
    Jain R; Laliberté F; Germain G; Mahendran M; Higa S; Harrington A; Parikh M
    J Manag Care Spec Pharm; 2023 Aug; 29(8):896-906. PubMed ID: 37523314
    [No Abstract]   [Full Text] [Related]  

  • 12. Annual costs among patients with major depressive disorder and the impact of key clinical events.
    Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
    J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
    [No Abstract]   [Full Text] [Related]  

  • 13. Incremental burden of comorbid major depressive disorder in patients with type 2 diabetes or cardiovascular disease: a retrospective claims analysis.
    Kangethe A; Lawrence DF; Touya M; Chrones L; Polson M; Evangelatos T
    BMC Health Serv Res; 2021 Aug; 21(1):778. PubMed ID: 34362353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System.
    Sussman M; O'sullivan AK; Shah A; Olfson M; Menzin J
    J Manag Care Spec Pharm; 2019 Jul; 25(7):823-835. PubMed ID: 31232205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Earlier Versus Later Augmentation with an Antipsychotic Medication in Patients with Major Depressive Disorder Demonstrating Inadequate Efficacy in Response to Antidepressants: A Retrospective Analysis of US Claims Data.
    Yermilov I; Greene M; Chang E; Hartry A; Yan T; Broder MS
    Adv Ther; 2018 Dec; 35(12):2138-2151. PubMed ID: 30456519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Cognitive Function and Health Care Costs 3 Months and 6 Months After Initiating Antidepressant Medication for Depressive Disorders.
    Walker V; Patel H; Kurlander JL; Essoi B; Yang J; Mahableshwarkar AR; Samp JC; Akhras KS
    J Manag Care Spec Pharm; 2015 Sep; 21(9):742-52, 752a-752e. PubMed ID: 26308222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder.
    Asche CV; Joish VN; Camacho F; Drake CL
    Curr Med Res Opin; 2010 Aug; 26(8):1843-53. PubMed ID: 20515321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease.
    King A; Rajpura J; Liang Y; Paprocki Y; Uzoigwe C
    Curr Med Res Opin; 2022 Nov; 38(11):1831-1840. PubMed ID: 36134459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.
    Zhdanava M; Teeple A; Pilon D; Shah A; Caron-Lapointe G; Joshi K
    J Med Econ; 2023; 26(1):691-700. PubMed ID: 37130075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is clinician impression of depression symptom severity associated with incremental economic burden in privately insured US patients with treatment resistant depression?
    Pilon D; Sheehan JJ; Szukis H; Morrison L; Zhdanava M; Lefebvre P; Joshi K
    J Affect Disord; 2019 Aug; 255():50-59. PubMed ID: 31128505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.